Prosecution Insights
Last updated: September 17, 2026
Application No. 18/254,465

A SERIES OF PYRROLE DERIVATIVES AND THEIR PREPARATION METHOD AND THERAPEUTIC USE

Final Rejection §112
Filed
Nov 30, 2023
Priority
Dec 21, 2020 — CN 202011519683.3 +2 more
Examiner
RAO, PADMAJA S
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shenzhen Sungening Bio-Medical Co. Ltd.
OA Round
2 (Final)
70%
Grant Probability
Favorable
3-4
OA Rounds
2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
109 granted / 155 resolved
+10.3% vs TC avg
Strong +36% interview lift
Without
With
+36.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
39 currently pending
Career history
196
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
31.1%
-8.9% vs TC avg
§102
17.1%
-22.9% vs TC avg
§112
25.8%
-14.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 155 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Claims 7, 12, 18, 20, 22, 29, 31 and 37-39 are pending as of the response and amendments filed 07/13/2026. Claims 1-6, 8-11, 13-17, 19, 21, 23-28, 30 and 32-36 are cancelled. Applicant’s original election of group I claims without traverse is maintained. Claims 29 and 31 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 7, 12, 18, 20, 22 and 37-39 are examined herein. The 37 CFR 1.121 objection of previous record is withdrawn in consideration of the correct status identifiers for the claims in the response dated 07/13/2026. The claim objections of previous record are withdrawn in consideration of the claim amendments. The 35 U.S.C. 112(b) rejection of previous record is partially withdrawn in consideration of the claim amendments. However, the 35 U.S.C. 112(b) rejection of claim 7 is maintained since the claim amendment does not remedy the indefiniteness due to the presence of the J, Y, T variables in the structure of a compound of Formula II. The 35 U.S.C. 112(d) rejection of previous record is rendered moot in view of the cancellation of claims 23 and 36. In view of the pending claims, the following rejections are made. Claim Rejections - 35 USC § 112 - Maintained The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7, 18, 20, 22 and 37 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 7, the claim recites Formula II with variables J, Y and T, that have not been defined in the claim, therefore causing some ambiguity regarding the scope of the claim. Therefore, the metes and bounds of claim 7 are indefinite. Claims 18, 20, 22 and 37 are similarly rejected because they depend from claim 7 and do not remedy the indefiniteness. The examiner suggests that the structure of Formula II be amended to be similar to the structure of Formula IV with the additional required variables of Formula II to overcome this rejection. Allowable Subject Matter Claims 12 and 38-39 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The reasons for the indication of allowable subject matter remains the same as stated in the Office action dated 06/05/2026, with the closest prior art being the Law et al. (US 2020/0338072 A1, 29 October 2020, hereinafter Law, in the IDS) and Xie et al. (US 2022/0340565 A1, PCT filing date of 02 December 2020, hereinafter Xie, of previous record) references. Conclusion Claims 7, 18, 20, 22 and 37 are rejected. Claims 12 and 38-39 are objected to. No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PADMAJA S RAO whose telephone number is (571)272-9918. The examiner can normally be reached 9:00-5:30 pm EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney L Klinkel can be reached on (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PADMAJA S RAO/Examiner, Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Nov 30, 2023
Application Filed
Apr 03, 2026
Response after Non-Final Action
Jun 05, 2026
Non-Final Rejection mailed — §112
Jul 13, 2026
Response Filed
Aug 13, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734139
ENSIFENTRINE FOR DECREASING THE FREQUENCY/SEVERITY OF COPD EXACERBATIONS
2y 7m to grant Granted Sep 15, 2026
Patent 12735411
COMPOSITIONS FOR TREATMENT OF OCULAR DISEASES
2y 9m to grant Granted Sep 15, 2026
Patent 12729204
HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF
3y 1m to grant Granted Sep 08, 2026
Patent 12721844
CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD
3y 10m to grant Granted Sep 01, 2026
Patent 12721821
PLANT ESSENTIAL OIL AMINO ACID COMPOSITION AND PREPARATION METHOD THEREFOR
3y 0m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
70%
Grant Probability
99%
With Interview (+36.5%)
3y 0m (~2m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 155 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month